Dmitriy Niyazov
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
With the rapid adoption and increasing use of genetic testing in pediatric neurology, the discovery and characterization of novel pathogenic variants resulting in neurodevelopmental and seizure disorders are becoming more common. One such disorder is EIF4A2‐ related neurodevelopmental disorder, a recently described disorder with various clinical associations, including developmental delay, epilepsy, and structural brain anomalies. In this case series, we describe two patients with pathogenic EIF4A2 variants, including one of the first detailed reports of a patient with EIF4A2 mosaicism, to add to the growing catalog of genotypic variability in this disorder, as well as a novel phenotypic finding of absent cochlear nerve. Both cases presented here involve patients who developed subtle, initially electrographically negative, epileptic spasms before going on to develop characteristic findings of infantile spasms requiring hormonal treatment. Together, these cases provide valuable information to guide future management of patients with EIF4A2 ‐related disorder.
Year:
2026
Molybdenum cofactor deficiency (MoCD) is an inborn error of metabolism included in the differential for refractory neonatal seizures. The prognosis is guarded, with a median reported age of death between 2.4 and 3.0 years. Mortality is primarily due to seizures and lower respiratory tract infections. MoCD has a distinct biochemical profile, characterized by elevated urinary S ‐sulfocysteine, xanthine, and hypoxanthine, and low or undetectable serum and urine uric acid levels. A disease‐altering treatment is available for MoCD Type A; however, due to the rarity of the condition, its natural history remains poorly understood. We present a patient with neonatal‐onset refractory seizures, whose biochemical testing, performed within 24 h of specimen receipt in the laboratory, revealed a pattern consistent with MoCD. Before the genetics team could disclose the preliminary diagnosis, the patient demised, without evidence of worsening seizures or respiratory infection. Results of genome sequencing, guided by biochemical findings, identified double homozygous pathogenic variants in MOCS1 (associated with MoCD Type A). Although the biochemical genetics laboratory's protocol for analyzing and reporting S ‐sulfocysteine levels within 48 h enabled a rapid preliminary diagnosis, the patient's condition deteriorated too quickly to initiate disease‐altering treatment, progressing more rapidly than described in the literature. We discuss potential hypotheses for his rapid decline and the broader implications for the field of biochemical genetics.
Year:
2026
Neurodevelopmental proteasomopathies represent a distinctive category of neurodevelopmental disorders (NDD) characterized by genetic variations within the 26S proteasome, a protein complex governing eukaryotic cellular protein homeostasis. In our comprehensive study, we identified 23 unique variants in PSMC5 , which encodes the AAA-ATPase proteasome subunit PSMC5/Rpt6, causing syndromic NDD in 38 unrelated individuals. Overexpression of PSMC5 variants altered human hippocampal neuron morphology, while PSMC5 knockdown led to impaired reversal learning in flies and loss of excitatory synapses in rat hippocampal neurons. PSMC5 loss-of-function resulted in abnormal protein aggregation, profoundly impacting innate immune signaling, mitophagy rates, and lipid metabolism in affected individuals. Importantly, targeting key components of the integrated stress response, such as PKR and GCN2 kinases, ameliorated immune dysregulations in cells from affected individuals. These findings significantly advance our understanding of the molecular mechanisms underlying neurodevelopmental proteasomopathies, provide links to research in neurodegenerative diseases, and open up potential therapeutic avenues.
Year:
2024
Collaborators (29)
Ype Elgersma
Full professor
Erasmus MC
Tamar Harel
-
Geeske van Woerden
Associate professor
Erasmus University Rotterdam
Rebecca Ganetzky
Associate Professor
Children's Hospital of Philadelphia
EFTERPI PAVLIDOU
Assistant Professor of Pediatrics
University of Ioannina
Peter Krawitz
University of Bonn
Dominique Bonneau
Professor of Medical Genetics
Université d'Angers
Arnaud Droit
Professor
Université Laval Faculté de médecine
Tzung-Chien Hsieh
University Hospital Bonn
Evan Eichler
Howard Hughes Medical Institute
Marie-Pierre Bousquet
Institute of Pharmacology and Structural Biology
Peter Werner Hildebrand
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Stéphane Bézieau
Université de Nantes
Andrew Dauber
The George Washington University School of Medicine and Health SCiences
Frederic Laumonnier
Team Leader, Research Director
INSERM
Renske Oegema
UMC Utrecht
Rami Abou Jamra
University Hospital Leipzig
Jens Meiler
Vanderbilt University
Kimberly McDonald
Assistant Professor
University of Mississippi Medical Center
Elke Hammer
University Medicine Greifswald
Elke Krueger
Director
University Medicine Greifswald
Tychele Turner
Assistant Professor
Washington University School of Medicine
Frédéric Ebstein
Group Leader
Université de Nantes
Andreas Grabrucker
Lecturer (Assist. Prof)
University of Limerick
Gregory Costain
Hospital for Sick Children
Antonio Vitobello
Full professor
Université de Bourgogne
Anita Rauch
University of Zurich
Julien Marcoux
CNRS Research Director
Institute of Pharmacology and Structural Biology
Miroslava Hancarova
Charles University
Make your next move.
Prepare your application
Review drafts before you send them.